Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Apr 20;24(1):262.
doi: 10.1186/s12887-024-04736-9.

The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial

Asghar Marzban  1 , Samira Mokhtari  1 , Pouria Tavakkolian  2 , Reza Mansouri  3 , Nahid Jafari  1 , Azam Maleki  4
Affiliations
Randomized Controlled Trial

The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial

Asghar Marzban et al. BMC Pediatr. .

Abstract

Background: Respiratory distress syndrome (RDS) is one of the most important and common disorders among premature infants.

Objective: This study aimed to compare the effect of the combination of surfactant and budesonide with surfactant alone on Bronchopulmonary dysplasia (BPD) and mortality rate among premature infants with RDS.

Method: An outcome assessor-blind randomized clinical trial was conducted on 134 premature infants with RDS who were born in Ayatollah Mousavi Hospital, Zanjan, Iran in 2021. The covariate adaptive randomization method was utilized to allocate participants into two groups (surfactant alone and a combination of surfactant and budesonide). The primary outcomes were BPD and Mortality rate from admission to hospital discharge. The data in this study were analyzed using SPSS software version 18.

Results: Overall the comparison of mortality rate and BPD between the two groups did not show a significant difference(p > 0.05). The subgroup results showed that administering surfactant with budesonide to infants under 30 weeks of age significantly reduced the number of deaths compared to using surfactant alone (5 vs. 17). Similar positive effects were observed for the occurrence of Pulmonary Hemorrhage, the need for a second dose of surfactant, oxygen index, mean blood pressure and mean arterial pressure (MAP) in infants under 34 weeks of age compared to more than 34 weeks (p < 0.05).

Conclusion: These findings suggest that the combination therapy of surfactant and budesonide may be beneficial, particularly in preterm infants with less than 34 weeks gestational age and 1500 birth weight. However, further studies with larger sample sizes and longer follow-up periods are needed to confirm these results and assess long-term outcomes.

Trial registration: The study was registered at the Iranian Registry of Clinical Trials website under the code IRCT20201222049802N1. https://en.irct.ir/user/trial/48117/view .

Registration date: 28/02/2021.

Public repository: DATA SET: This research data set link is displayed on the Zanjan-Iran Medical Sciences website: https://repository.zums.ac.ir/cgi/users/login? target=https%3 A%2 F/repository.zums.ac.ir/id/eprint .

Keywords: Budesonide; Premature neonate; Respiratory distress syndrome; Surfactant.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported

Figures

Fig. 1
Fig. 1
CONSORT flow diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chowdhury N, Giles BL, Dell SD. Full-term neonatal respiratory distress and chronic lung disease. Pediatr Ann. 2019;48(4):e175–81. doi: 10.3928/19382359-20190328-01. - DOI - PubMed
    1. Isayama T, Lee SK, Yang J, Lee D, Daspal S, Dunn M, et al. Revisiting the definition of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates. JAMA Pediatr. 2017;171(3):271–9. doi: 10.1001/jamapediatrics.2016.4141. - DOI - PubMed
    1. De Luca D, Tingay DG, Van Kaam AH, Courtney SE, Kneyber MC, Tissieres P, et al. Epidemiology of neonatal acute respiratory distress syndrome: prospective, multicenter, international cohort study. Pediatr Crit Care Med. 2022;23(7):524–34. doi: 10.1097/PCC.0000000000002961. - DOI - PubMed
    1. Mohammadizadeh M, Ardestani AG, Sadeghnia AR. Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome: feasibility and outcome. J Res Pharm Pract. 2015;4(1):31. doi: 10.4103/2279-042X.150053. - DOI - PMC - PubMed
    1. Yao S, Uthaya S, Gale C, Modi N, Battersby C. Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England and Wales 2012–2019: a retrospective population cohort study. BMJ open. 2022;12(11):e063835. doi: 10.1136/bmjopen-2022-063835. - DOI - PMC - PubMed

Publication types